- About MicuRx
- Scientific research
- Newsroom
-
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
J Pharmacokinet Pharmacodyn / 2019View Publication
-
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Clinical Therapeutics / 2018View Publication
-
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis
Antimicrob Agents Chemother / 2018View Publication
-
Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
Antimicrob Agents Chemother / 2017View Publication
-
Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes
Drug Metab Dispos / 2015View Publication
-
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile
J Med Chem / 2014View Publication
-
Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
Int J Antimicrob Agents / 2014View Publication
-
In vivo Antibacterial Activity of MRX-I, a New Oxazolidinone
Antimicrob Agents Chemother / 2014View Publication
- Scientific research
